Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
- Eli Lilly: 15 events in the last 90 days
- Previous: earlier the same day · Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
What happened
EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes
Summary assembled by rule from the sources below